NYSE:KDMN Kadmon (KDMN) Stock Price, News & Analysis → It’s now possible to know the win rate of every trade… BEFORE you take it! (From WealthPress) (Ad) Free KDMN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$9.50▼$9.5050-Day Range$9.50▼$9.5052-Week Range$3.19▼$9.50Volume1,052 shsAverage Volume5.11 million shsMarket Capitalization$1.70 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Kadmon alerts: Email Address Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! About Kadmon Stock (NYSE:KDMN)Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.Read More Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! KDMN Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive KDMN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kadmon and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNYSE SectorManufacturing Industry Pharmaceutical Preparation Manufacturing Sub-IndustryN/A Current SymbolNYSE:KDMN CUSIPN/A CIKN/A WebN/A Phone12123086000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares178,521,000Free FloatN/AMarket Cap$1.70 billion OptionableOptionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key CompetitorsBlackRock Capital Allocation Term TrustNYSE:BCATiShares Fallen Angels USD Bond ETFNASDAQ:FALNInvesco KBW Bank ETFNASDAQ:KBWBFirst Trust Exchange-Traded Fund IV First Trust Tactical High Yield ETFNASDAQ:HYLSFirst Trust Managed Municipal ETFNASDAQ:FMBView All Competitors KDMN Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Kadmon own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kadmon investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Organigram (OGI), KushCo (KSHB), Gran Tierra Energy (GTE), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), Auxly Cannabis Group (CBWTF) and CNBX Pharmaceuticals (CNBX). When did Kadmon IPO? Kadmon (KDMN) raised $101 million in an IPO on Wednesday, July 27th 2016. The company issued 5,600,000 shares at a price of $16.00-$20.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers. This page (NYSE:KDMN) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kadmon Holdings Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
